Psoriasis, psoriatic arthritis, metabolic disorders and cardiovascular disease. What is common?

Close metadata

Recommended articles:

Psoriasis exudativa in patient with hereditary hemorrhagic telangiectasia. Russian Journal of Clinical Dermatology and Venereology. 2024;(4):356-361

Psoriasis in pregnant women. Russian Journal of Clinical Dermatology and Venereology. 2024;(5):517-524

Pathology of the kidneys in malignant tumors of various localizations and antitumor therapy. Russian Journal of Archive of Pathology. 2024;(3):59-66

Morbidity of Psoriasis and psoriatic arthritis in the Republic of Bashkortostan in 2012—2022. Russian Journal of Preventive Medicine. 2024;(7):38-45

Features of cognitive impairment in bipolar affective disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):56-64

Prospective assessment of surgical stress response in patients with craniosynostosis: comparison of clinical and laboratory data. Burdenko's Journal of Neurosurgery. 2024;(4):62-70

Possibilities of coronary artery calcification assessment for cardiovascular risk stratification. Russian Journal of Preventive Medicine. 2024;(9):117-122

Continuum of type 2 diabetes mellitus and its comorbidity with other somatic diseases. Russian Journal of Preventive Medicine. 2024;(9):123-129

Psoriasis is a chronic immuno-inflammatory skin disease characterized by impaired proliferation and differentiation of epidermal keratinocytes involving both innate and adaptive immunity. The prevalence of psoriasis in the population is 1—4%. Recently, in connection with new data on the pathogenesis of the disease and the emergence of modern methods of treatment, such as biological therapy, it is important to have an idea of concomitant diseases, in particular cardiovascular. The literature review presents current data on the frequency of comorbidity of psoriasis, psoriatic arthritis with cardiovascular diseases and risk factors (coronary heart disease, diabetes mellitus, metabolic syndrome, obesity, arterial hypertension and dyslipidemia) and the general pathogenesis of these conditions. Discussed the results of meta-analyzes of randomized clinical trials on the association of psoriasis with cardiovascular diseases, in particular with the prevalence and severity of coronary atherosclerosis. Marked the pathogenetic role of interleukin-17 in the formation of these diseases and the effectiveness of modern biological therapy for treating not only psoriasis and psoriatic arthritis, but also metabolic disorders and cardiovascular diseases. Identified the future possibilities of biological therapy in reducing cardiovascular inflammation.

Keywords:

psoriasis

psoriatic arthritis

metabolic disorders

cardiovascular disease

comorbidity

Authors:

Khismatullina Z.R.

Bashkir State Medical University, Ministry of Health of the Russian Federation, Ufa, Russia, 450000

Amineva A.M.

Bashkir State Medical University of the Ministry of Health of Russia, Ufa, Russia

Kurochkin D.P.

Bashkir State Medical University of the Ministry of Health of Russia, Ufa, Russia

Gareeva D.F.

Bashkir State Medical University of the Ministry of Health of Russia, Ufa, Russia

Zagidullin N.S.

Bashkir State Medical University, Russian Ministry of Health, Ufa, Russia

List of references:

Husted J, Thavaneswaran A, Chandran V, Eder L, Rosen C, Cook R, Gladman D. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care & Research. 2011;63(12):1729-1735. https://doi.org/10.1002/acr.20627
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76:393-403. https://doi.org/10.1016/j.jaad.2016.07.065
Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-307. https://doi.org/10.1111/j.1600-0625.2011.01261.x
Koch M, Baurecht H, Ried JS, Rodriguez E, Schlesinger S, Volks N, Gieger C, Rückert IM, Heinrich L, Willenborg C. Psoriasis and cardiometabolic traits: Modest association but distinct genetic architectures. J Investig Dermatol. 2015;135:1283-1293. https://doi.org/10.1038/jid.2015.8
Sundarrajan S, Arumugam M. Comorbidities of psoriasis — Exploring the links by network approach. PLoS ONE. 2016;11:e0149175. https://doi.org/10.1371/journal.pone.0149175
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645-653. https://doi.org/10.1016/j.jaci.2017.07.004
Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013;339:172-177. https://doi.org/10.1126/science.1230721
Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. https://doi.org/10.1155/2014/943162
Stelzner K, Herbert D, Popkova Y, Lorz A, Schiller J, Gericke M, Klöting N, Blüher M, Franz S, Simon JC. Free fatty acids sensitize dendritic cells to amplify Th1/Th17 cell-immune responses. Eur J Immunol. 2016;46:2043-2053. https://doi.org/10.1002/eji.201546263
McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Zhang H. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arteroscler Thromb Vasc Biol. 2014;34:2637-2643. https://doi.org/10.1161/ATVBAHA.114.304636
Bertrand MJ, Tardif JC. Inflammation and beyond: New directions and emerging drugs for treating atherosclerosis. Expert Opin Emerg Drugs. 2017; 22:1-26. https://doi.org/10.1080/14728214.2017.1269743
Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X, Baugous B, Johnston A, Joshi AA, Silverman J. IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep. 2017;7(1):13831. https://doi.org/10.1038/s41598-017-14365-1
Klarin D, Zhu QM, Emdin CA, Chaffin M, Horner S, McMillan BJ, Leed A, Weale ME, Spencer CCA, Aguet F. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet. 2017;49:1392-1397. https://doi.org/10.1038/ng.3914
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol. 2013;149:1173-1179. https://doi.org/10.1001/jamadermatol.2013.5015
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741. https://doi.org/10.1001/jama.296.14.1735
Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062. https://doi.org/10.1161/JAHA.113.000062
Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ, Rodante J, Lerman JB, Ahlman MA, Gelfand JM. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77:650-656. https://doi.org/10.1016/j.jaad.2017.06.028
Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232:633-639. https://doi.org/10.1159/000455840
Snekvik I, Smith CH, Nilsen TIL, Langan SM, Modalsli EH, Romundstad PR, Saunes M. Obesity, waist circumference, weight change, and risk of incident psoriasis: Prospective data from the HUNT study. J Investig Dermatol. 2017;137:2484-2490. https://doi.org/10.1016/j.jid.2017.07.822
Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: A systematic review. Br J Dermatol. 2013;168:486-495. https://doi.org/10.1111/bjd.12101
Srinivas S, Nagendra S, Goudappala, Kashinath RT. Alterations in plasma lipid profile and cardiovascular risk indicators in clinically sub-grouped psoriasis. Int J Res Dermatol. 2019;5(2):2455-4529. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20190429
Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, Rosen CF, Gladman DD. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2013;72:715-720. https://doi.org/10.1136/annrheumdis-2012-201497
Shen J, Wong KT, Cheng IW. Increased Prevalence of Coronary Plaque in Patients With Psoriatic Arthritis Without Prior Diagnosis of Coronary Artery Disease. Ann Rheum Dis. 2017;76(7):1237-1244. https://doi.org/10.1136/annrheumdis-2016-210390
Kaiser H, Abdulla J, Henningsen KMA, Skov L, Hansen PR. Coronary Artery Disease Assessed by Computed Tomography in Patients with Psoriasis: A Systematic Review and Meta-Analysis. Dermatology. 2019;235(6):478-487. https://doi.org/10.1159/000502138
Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE. Psoriasis and smoking: A systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016;20:221-227. https://doi.org/10.1177/1203475415616073
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD. CANTOS trial group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131. https://doi.org/10.1056/NEJMoa1707914
Roubille C, Richer V, Starnino T, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-489. https://doi.org/10.1136/annrheumdis-2014-206624
Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, Mozaffarian D. Systematic review and metaanalysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362-1370. https://doi.org/10.1016/j.amjcard.2011.06.054
Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-1250. https://doi.org/10.1001/archdermatol.2012.2502
Yang ZS, Lin NN, Li L, Li Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis. Clin Rev Allergy Immunol. 2016;51:240-247. https://doi.org/10.1007/s12016-016-8560-9
Piaserico S, Osto E, Famoso G, Zanetti I, Gregori D, Poretto A, Iliceto S, Peserico A, Tona F. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis. 2016;251:25-30. https://doi.org/10.1016/j.atherosclerosis.2016.05.036
Avgerinou G, Tousoulis D, Siasos G, Oikonomou E, Maniatis K, Papageorgiou N, Paraskevopoulos T, Miliou A, Koumaki D, Latsios G. Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol. 2011;151:382-383. https://doi.org/10.1016/j.ijcard.2011.06.112
Tam L, Li E, Shang Q, Tomlinson B, Li M, Leung YY, Kuan WP, Kwok LW, Li TK, Zhu Y. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: A 2-year pilot study. Ann Rheum Dis. 2011;70:705-706. https://doi.org/10.1136/ard.2010.131359
Mazzoccoli G, Notarsanto I, de Pinto GD, Dagostino MP, De Cata A, D’Alessandro G, Tarquini, R, Vendemiale G. Anti-tumor necrosis factor-α therapy and changes of ﬂow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med. 2010;5:495-500. https://doi.org/10.1007/s11739-010-0458-6
Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, Harrington CL, Rivers JP, Chung JH. Association between skin and aortic vascular inﬂammation in patients with psoriasis: A case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol. 2017;2:1013-1018. https://doi.org/10.1001/jamacardio.2017.1213
Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. JEADV. 2019 Oct 10. https://doi.org/10.1111/jdv.16004
Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, Rodante J, Harrington CL, Teague HL, Baumer Y, Keel A, Playford MP, Sandfort V, Chen MY, Lockshin B, Gelfand JM, Bluemke DA, Mehta NN. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721-728. https://doi.org/10.1093/cvr/cvz009

Close metadata